MIL93 / Beijing Mabworks Biotech - LARVOL DELTA

A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov) - P1 | N=228 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Aug 2023 ➔ Aug 2025 | Trial primary completion date: Aug 2023 ➔ Aug 2025

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18

A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov) - P1 | N=228 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Feb 2023 ➔ Aug 2023

Metastases • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18

Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18.2 monoclonal antibody, in patients with advanced solid tumors: A phase 1 clinical study. (ASCO 2022) - P1 | "MIL93 had a favorable safety profile with no DLTs observed through 20mg/kg Q3W. Pts with CLDN18.2-positive gastric cancer responded to the treatment. Dose escalation and expansion in selected tumor types is currently underway."

Clinical • P1 data • PK/PD data • Anemia • Esophageal Cancer • Fatigue • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • CLDN8

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial. (ASCO-GI 2023) - P1 | "MIL93 is a humanized afucosylated IgG1 monoclonal antibody targeting CLDN18.2 with enhanced ADCC function, which demonstrated superior activity compared with zolbetuximab in vitro and in vivo, respectively. MIL93 had a manageable and tolerable safety profile in patients with advanced solid tumors and preliminary anti-tumor activity in 2 heavily pretreated gastric cancer pts. Combination of MIL93 and standard treatment in selected tumor types is currently underway. Clinical trial information: NCT04671875."

Clinical • Metastases • Monotherapy • P1 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • CLDN8

A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov) - P1 | N=228 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18

A Clinical Study of MIL93 in Solid Tumors. (clinicaltrials.gov) - P1; N=228; Not yet recruiting; Sponsor: Beijing Mabworks Biotech Co., Ltd.

Clinical • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor